Key Points
- Director Matthew Posard sold 5,230 Halozyme shares at an average price of $108.54, generating $567,664.20. The sale, conducted under a Rule 10b5-1 plan, reduced his direct ownership by 8.89% to 53,609 shares.
- Halozyme reported strong quarterly results, with $2.28 earnings per share and $481 million in revenue, beating estimates and marking 47.7% year-over-year revenue growth. The company issued fiscal 2026 EPS guidance of $8.65–$9.00.
- Analysts maintain a generally positive view, with nine Buy ratings, three Holds, and one Sell, resulting in a “Moderate Buy” consensus. Institutional investors own 97.79% of the company, while the stock recently traded near its 52-week high.
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Matthew Posard sold 5,230 shares of Halozyme Therapeutics stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $108.54, for a total value of $567,664.20. Following the transaction, the director directly owned 53,609 shares in the company, valued at approximately $5,818,720.86. This trade represents a 8.89% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Halozyme Therapeutics Price Performance
NASDAQ HALO opened at $109.86 on Friday. The company has a 50 day simple moving average of $103.50 and a 200-day simple moving average of $81.45. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The firm has a market capitalization of $12.47 billion, a price-to-earnings ratio of 32.79, a price-to-earnings-growth ratio of 0.41 and a beta of 0.88. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $116.85.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million during the quarter, compared to analysts' expectations of $402.28 million. During the same period last year, the company posted $1.54 earnings per share. The firm's quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research firms have recently commented on HALO. Wells Fargo & Company boosted their price target on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an "equal weight" rating in a report on Friday, August 7th. Leerink Partners upgraded Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and increased their price objective for the stock from $83.00 to $110.00 in a report on Friday, August 7th. Benchmark reissued a "buy" rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Citigroup restated a "market outperform" rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Finally, TD Cowen upped their target price on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $91.20.
Get Our Latest Stock Analysis on HALO
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Bank of America Corp DE acquired a new position in Halozyme Therapeutics during the second quarter worth $214,504,000. William Blair Investment Management LLC bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth about $196,540,000. Norges Bank acquired a new position in shares of Halozyme Therapeutics during the 4th quarter valued at about $128,201,000. Jupiter Topco LLC bought a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at approximately $105,570,000. Finally, Caisse de depot et placement du Quebec acquired a new stake in Halozyme Therapeutics in the 2nd quarter worth approximately $83,940,000. Institutional investors own 97.79% of the company's stock.
About Halozyme Therapeutics
(
Get Free Report)
Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.
Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
